TY - JOUR
T1 - Virus nomenclature below the species level
T2 - A standardized nomenclature for filovirus strains and variants rescued from cDNA
AU - Kuhn, Jens H.
AU - Bào, Yimíng
AU - Bavari, Sina
AU - Becker, Stephan
AU - Bradfute, Steven
AU - Brauburger, Kristina
AU - Rodney Brister, J.
AU - Bukreyev, Alexander A.
AU - Caì, Yíngyún
AU - Chandran, Kartik
AU - Davey, Robert A.
AU - Dolnik, Olga
AU - Dye, John M.
AU - Enterlein, Sven
AU - Gonzalez, Jean Paul
AU - Formenty, Pierre
AU - Freiberg, Alexander N.
AU - Hensley, Lisa E.
AU - Hoenen, Thomas
AU - Honko, Anna N.
AU - Ignatyev, Georgy M.
AU - Jahrling, Peter B.
AU - Johnson, Karl M.
AU - Klenk, Hans Dieter
AU - Kobinger, Gary
AU - Lackemeyer, Matthew G.
AU - Leroy, Eric M.
AU - Lever, Mark S.
AU - Mühlberger, Elke
AU - Netesov, Sergey V.
AU - Olinger, Gene G.
AU - Palacios, Gustavo
AU - Patterson, Jean L.
AU - Paweska, Janusz T.
AU - Pitt, Louise
AU - Radoshitzky, Sheli R.
AU - Ryabchikova, Elena I.
AU - Saphire, Erica Ollmann
AU - Shestopalov, Aleksandr M.
AU - Smither, Sophie J.
AU - Sullivan, Nancy J.
AU - Swanepoel, Robert
AU - Takada, Ayato
AU - Towner, Jonathan S.
AU - van der Groen, Guido
AU - Volchkov, Viktor E.
AU - Volchkova, Valentina A.
AU - Wahl-Jensen, Victoria
AU - Warren, Travis K.
AU - Warfield, Kelly L.
AU - Weidmann, Manfred
AU - Nichol, Stuart T.
N1 - Funding Information:
The content of this publication does not necessarily reflect the views or policies of the US Department of the Army, the US Department of Defense or the US Department of Health and Human Services or of the institutions and companies affiliated with the authors. This work was funded in part by the Joint Science and Technology Office for Chem Bio Defense (proposal #TMTI0048_09_RD_T to SB). YC, JHK, and VWJ performed this work as employees of Tunnell Consulting, Inc., and MGL as an employee of Lovelace Respiratory Research Institute, both subcontractors to Battelle Memorial Institute under its prime contract with NIAID, under Contract No. HHSN272200700016I. This research was also supported in part by the Intramural Research Program of the NIH, National Library of Medicine (YB and JRB), and the Intramural Research Program of the NIH, NIAID (TH).
PY - 2014/5
Y1 - 2014/5
N2 - Specific alterations (mutations, deletions, insertions) of virus genomes are crucial for the functional characterization of their regulatory elements and their expression products, as well as a prerequisite for the creation of attenuated viruses that could serve as vaccine candidates. Virus genome tailoring can be performed either by using traditionally cloned genomes as starting materials, followed by site-directed mutagenesis, or by de novo synthesis of modified virus genomes or parts thereof. A systematic nomenclature for such recombinant viruses is necessary to set them apart from wild-type and laboratory-adapted viruses, and to improve communication and collaborations among researchers who may want to use recombinant viruses or create novel viruses based on them. A large group of filovirus experts has recently proposed nomenclatures for natural and laboratory animal-adapted filoviruses that aim to simplify the retrieval of sequence data from electronic databases. Here, this work is extended to include nomenclature for filoviruses obtained in the laboratory via reverse genetics systems. The previously developed template for natural filovirus genetic variant naming, (/)///-, is retained, but we propose to adapt the type of information added to each field for cDNA clone-derived filoviruses. For instance, the full-length designation of an Ebola virus Kikwit variant rescued from a plasmid developed at the US Centers for Disease Control and Prevention could be akin to "Ebola virus H.sapiens-rec/COD/1995/Kikwit-abc1" (with the suffix "rec" identifying the recombinant nature of the virus and "abc1" being a placeholder for any meaningful isolate designator). Such a full-length designation should be used in databases and the methods section of publications. Shortened designations (such as "EBOV H.sap/COD/95/Kik-abc1") and abbreviations (such as "EBOV/Kik-abc1") could be used in the remainder of the text, depending on how critical it is to convey information contained in the full-length name. "EBOV" would suffice if only one EBOV strain/variant/isolate is addressed.
AB - Specific alterations (mutations, deletions, insertions) of virus genomes are crucial for the functional characterization of their regulatory elements and their expression products, as well as a prerequisite for the creation of attenuated viruses that could serve as vaccine candidates. Virus genome tailoring can be performed either by using traditionally cloned genomes as starting materials, followed by site-directed mutagenesis, or by de novo synthesis of modified virus genomes or parts thereof. A systematic nomenclature for such recombinant viruses is necessary to set them apart from wild-type and laboratory-adapted viruses, and to improve communication and collaborations among researchers who may want to use recombinant viruses or create novel viruses based on them. A large group of filovirus experts has recently proposed nomenclatures for natural and laboratory animal-adapted filoviruses that aim to simplify the retrieval of sequence data from electronic databases. Here, this work is extended to include nomenclature for filoviruses obtained in the laboratory via reverse genetics systems. The previously developed template for natural filovirus genetic variant naming, (/)///-, is retained, but we propose to adapt the type of information added to each field for cDNA clone-derived filoviruses. For instance, the full-length designation of an Ebola virus Kikwit variant rescued from a plasmid developed at the US Centers for Disease Control and Prevention could be akin to "Ebola virus H.sapiens-rec/COD/1995/Kikwit-abc1" (with the suffix "rec" identifying the recombinant nature of the virus and "abc1" being a placeholder for any meaningful isolate designator). Such a full-length designation should be used in databases and the methods section of publications. Shortened designations (such as "EBOV H.sap/COD/95/Kik-abc1") and abbreviations (such as "EBOV/Kik-abc1") could be used in the remainder of the text, depending on how critical it is to convey information contained in the full-length name. "EBOV" would suffice if only one EBOV strain/variant/isolate is addressed.
UR - http://www.scopus.com/inward/record.url?scp=84899932651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899932651&partnerID=8YFLogxK
U2 - 10.1007/s00705-013-1877-2
DO - 10.1007/s00705-013-1877-2
M3 - Article
C2 - 24190508
AN - SCOPUS:84899932651
SN - 0304-8608
VL - 159
SP - 1229
EP - 1237
JO - Archives of virology
JF - Archives of virology
IS - 5
ER -